

Jim Finster
Lohocla Research Corporation
(303) 645-3788
jim@lohocla.com

FOR IMMEDIATE RELEASE: 28 Feb 2020

Local Biotech Firm Attracts Substantial NIH Funding for Drug Alternative to Opiates

Focusing on Non-addictive Pain Treatment, Lohocla Research Corporation Attracts National Institute on Drug Abuse Attention with Their Multi-target, Rationally Designed Therapeutic

Aurora, CO: Today, Lohocla Research Corporation announced that it received its 3.3 million-dollar second year of federal funding (of a total 15 million-dollar award) after meeting the milestones set out in their proposed research project into a non-addictive therapeutic for chronic pain.

Acknowledging the promise of this new drug, dubbed Kindolor, the National Institute on Drug Abuse (NIDA) has committed five years of funding to researching the safety and effectiveness of the new, rationally designed chemical entity.

Over 100 million adults in the U.S. suffer from intermittent or constant chronic pain. Moreover, chronic pain affects at least 10 percent of the world's population. The primary pharmaceuticals for treatment of chronic pain have been natural or synthetic opioids, which has resulted in what has been called an "epidemic" of opioid abuse, addiction and lethal overdoses.¹ This crisis is the result of the lack of good prescription alternatives to opiates in order to treat chronic pain.

Kindolor is significant because it can effectively treat chronic pain by actin on the peripheral nervous system. In contrast, opiates work primarily in the central nervous system, spinal cord, and brain, and so cause addiction. Moreover, not only is Kindolor able to ease pain on its own, it can be used in concert with opiates in order to reduce the necessary opiate dosage, mitigating the risk of opiate abuse and overdose.

Company CEO Dr. Boris Tabakoff said, "The breakthrough was the design of a molecule that addresses three important generators of chronic pain without affecting other targets. We have demonstrated that this approach results in a very effective medication that could truly work as a substitute for or adjunct to opiates and could reduce opiate use several fold."

About Lohocla Research: Lohocla Research Corporation is a compassionate company dedicated to improving quality of life. We understand the challenges associated with chronic pain and addiction and focus on transforming the lives of patients suffering from these conditions. The mission of Lohocla Research Corporation is to use genetic, genomic, and proteomic technology in conjunction with rational, computational drug design to develop diagnostic and therapeutic products for neurologic mental illness and/or addictive disorders.

www.lohocla.com

¹ <https://www.cdc.gov/drugoverdose/epidemic/index.html>